Medco class settlement remanded for review
A trial judge must determine whether the lead plaintiffs in a $42.5 mil. class action settlement with Medco had standing to bring the action, a New York-based federal appeals court ruled Dec. 8. The lower court failed to determine whether plaintiffs had demonstrated the required "injury-in-fact" necessary to gain standing to claim that Medco violated its fiduciary obligations, the appeals court said. The settlement, which was reached in 2002, faces objections from self-funded benefit plans that were Medco clients (1"The Pink Sheet" Dec. 16, 2002, p. 14)...
You may also be interested in...
Medco will disclose drug costs after rebates and discounts when the PBM wants to make a therapeutic interchange to a product with a higher AWP
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.